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clinical trials. If significant local relapse is prevalent in the high dose 
region then dose escalation could be considered. Using this technique, 
PET-CT imaging during treatment may identify those patients more 
likely to relapse locally allowing earlier salvage therapy. 
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Purpose/Objective: We previously showed that a moderately 
hypofractionated RT with Tomotherapy (41.4 Gy in 18 fractions) 
concomitant to oxaliplatin and 5-FU is effective and well tolerated 
and that rectal volume variations, assessed by daily MVCT performed 
by tomotherapy, are smaller and more stable during the second half 
of the treatment so that a margin of 0.5 cm around the rectum is 
sufficient to include more than 90% of its volumetric variations. These 
data, and the hypothesis that the residual tumor still visible on 
CT/MRI after 10 radiotherapy fractions and two cycles of 
chemotherapy, could represent a more radio-chemo resistant 
component of disease, suggest the adoption of adaptive tomotherapy 
approach in rectal cancer. 
The aim of the study was to investigate the feasibility of preoperative 
adaptive radio-chemotherapy by delivering a concomitant boost to the 
residual tumour during the last 6 fractions of treatment. 
 Materials and Methods: Twenty-five patients with T3/T4N0 or N+ 
rectal cancer were enrolled. Concomitant chemotherapy consisted of 
Oxaliplatin 100mg/m2 on days -14, 0, +14, and 5-FU 200mg/m2/day 
from day -14 to the end of radiotherapy (day 0 is the start of 
Radiotherapy). Radiotherapy consisted in the delivery of 41.4 Gy in 18 
fractions (2.3 Gy/fraction) with Tomotherapy to the tumor and 
regional lymph-nodes (PTV) defined on CT/MRI imaging. After 9 
fractions CT and MR were repeated for the planning of the adaptive 
phase: PTVadapt was generated by adding a 5mm margin to the residual 
tumour. In the last 6 fractions, a boost of 3.0 Gy/fr (in total 45.6 Gy 
in 18 fractions) was delivered to PTVadapt while concomitantly 
delivering 2.3 Gy/fr to PTV outside PTVadapt. 
Results: Three patients experienced G3 gastrointestinal toxicity; 
toxicity occurred before the adaptive phase in 2/3 patients. A full 
dose of RT, Oxaliplatin, and 5-FU was delivered in 96%, 96%, and 88% 
of patients, respectively. Two patients with clinical complete 
response (cCR) refused surgery and were still cCR at 17 and 29 
months. For the remaining 23 resected patients, 15/23 (65%) showed 
TRG3 response and 7/23 had pathological complete response (pCR, 
30%); 8 (35%) and 12 (52%) TRG3 patients had ≤5% and 10% residual 
viable cells respectively. When considering cCR+pCR+TRG3 with viable 
cells<10%, the rate of major response was 84% (21/25). 
Conclusions: Adaptive boost strategy is feasible with an acceptable 
G3 GI toxicity rate and a very encouraging tumour response rate. The 
results suggest that there should still be room for further dose 
escalation with the aim of increasing pCR and/or cCR rates. 
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Purpose/Objective: To access the efficacy and safety of salvage 
oesophagectomy after failed definitive chemoradiotherapy for 
advanced esophageal cancer. 
Materials and Methods: A systematically literature searches of 
Medline, Embase, ISI Web of Knowledge, Cochrane Library and China 
Biological Medicine Database were undertaken in October 
2012.Clinical studies about salvage oesophagectomy were included 
without language or study design restriction. The studies of a sample 
less than 10 were excluded for inexperience of salvage 
oesophagectomy. The primary outcomes were survival and 
complication. The quality of including studies was accessed using the 
Oxford 2011 Levels of Evidence. Hazard ratios (HRs) for overall 
survival (OS) were combined with an inverse variance method based 
on logarithmic conversion. Odds ratios (ORs) and mean difference 
(MD) with 95% confidence intervals (CIs) were used to analyze 
dichotomous and continuous variables, respectively. All statistical 
analyses were undertaken in Review Manager 5.1 and random effect 
model was used. 
Results: Ten studies (8 cohort and 2 uncontrolled studies) were 
included, the quality of included studies was poor. Overall 307 
patients performed salvage oesophagectomy. The 1-, 3-and 5-years OS 
rates in salvage oesophagectomy group based on 265 patients were 
66%, 41%, and 32%, respectively. Pooled analyses based on 2 studies 
demonstrated that salvage oesophagectomy was associated with 
longer survival than non-surgery treatment after local failure of 
definitive chemoradiotherapy, the HR of OS was 0.39(95%CI:0.24-0.65; 
p=0.0003). but when compared with planned surgery, meta-analyses 
based on 6 studies suggested that salvage oesophagectomy was 
associated with worse survival (HR=1.66,95% CI:1.11-2.47; p=0.01), 
and higher in-hospital mortality (OR=2.99,95%CI:1.67-5.35;p=0.0002), 
longer hospital stay (MD=8.35,95%CI:1.86- 14.85; p=0.01),more 
anastomotic leak (OR=2.56,95%CI:1.38-4.74;p=0.003), more wound 
infection(OR=1.98,95%CI:1.10-3.59; p=0.02), more pulmonary event 
(OR=1.86,95%CI:1.32-2.63; p=0.004).The primary prognostic factors 
for favorable survival after salvage oesophagectomy were complete 
resection (HR=3.76; p<0.00001) based on 5 studies and early tumor 
stage (HR=7.5; p=0.08)based on 3 studies. One including study 
reported that the outcome in patients with remnant tumors was 
poorer than in those with recurrence (p<0.01). 
Conclusions: With the rare clinical evidence, salvage oesophagectomy 
was considered as a hopeful treatment after local failure of definitive 
CRT. But with more complication and higher surgical difficulties than 
planned surgery, patients should be chosen more carefully. 
Meanwhile, higher surgical technique was required on surgeon. 
Because of the small sample and the low quality of current studies, 
more clinical studies are still needed. 
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Purpose/Objective: To retrospectively evaluate efficacy and toxicity 
of radio- ± chemotherapy (RT ± CT) in the management of anal canal 
carcinoma. 
Materials and Methods: Data of patients (pts) with an histological 
diagnosis of anal canal carcinoma were reviewed. Local Control (LC) 
and the acute and late toxicity rates were the primary endpoints of 
the analysis.Secondary endpoints are listed in Table 1. 
Results: From 02/1992 to 10/2010, 100 pts (M/F ratio: 17/83)were 
treated with curative RT with (58 pts) or without (42 pts) 
chemotherapy. Median age was 70 years (range: 33-91). According to 
the 2002 UICC TMN classification,13, 51, 14 and 22 tumors were 
staged as Stage I, II, IIIa and IIIb,respectively. 29% of the pts were N1-
3 and 14 pts presented positive inguinal nodes. Following the clinical 
conditions, RT was delivered on the initial tumor site with (68%) or 
without (32%) pelvic irradiation (upper field border: L5-S1) with a 
standard fractionation (1.8/2Gy). Median dose on the pelvis was 45Gy 
(range: 36-54), while a median total dose of 60Gy (range: 38-70)was 
delivered on the anal canal. Bilateral inguinal irradiation was 
delivered in 70 pts,with a curative (13%, one groin N+ patient having 
received lymphadenectomy before RT) or a prophylactic (57%) goal, at 
a median dose of 36Gy (range:36-66.6Gy). Median LC time was not 
reached, while 5- and10-years LC rates were 73% and 67%, 
respectively. Overall acute and late G3-4 toxicity rates were 32% 
(particularly skin G3 toxicity, 30/32 pts) and 18% (particularly rectal 
G3 toxicity, 7/18 pts), respectively, with 22 pts having undergo a 
colostomy, but with only 2 pts having received it to treat a G4 anal 
toxicity. All these pts received colostomy in the first 3 years after the 
end of the RT±CT. Sphincter function was evaluated in the remaining 
78 pts (with the Womack scale) and classified as a total continence or 
incontinence to gazes (score A-B) in 73 pts and a sincontinence to 
liquid stools (score C) in 5 pts or total incontinence (score D) in 2 pts. 
Table 1 shows results of the univariate and multivariate analysis on 
the primary and secondary endpoints. 
 
